An Open-label Phase 4 Study to Evaluate the Immunogenicity and Safety of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
Latest Information Update: 07 Dec 2021
At a glance
- Drugs BLB 750 (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Takeda
- 26 Mar 2018 Status changed from active, no longer recruiting to completed.
- 16 Jan 2018 Planned End Date changed from 25 Feb 2018 to 31 Mar 2018.
- 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.